Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion

Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”), with its wholly-owned subsidiary Celgene Corporation (“Celgene”) (collectively, the “Offerors”), announced the accepted amounts and pricing terms of their previously announced 20 separate offers to purchase for cash notes issued by the Offerors listed in the tables below for up to an aggregate purchase price of $4.0 billion.

The table below indicates, among other things, the aggregate principal amount of Notes tendered as of 5:00 p.m. (New York City time) on February 18, 2021 (the “Early Tender Deadline”) and accepted in each Offer, the Offer Yield (each as defined below), the proration factor, if any, and the total consideration for each $1,000 principal amount of each series of Notes validly tendered at or prior to the Early Tender Deadline and accepted for purchase (the “Total Consideration”), as calculated at 11:00 a.m. (New York City time) today, February 19, 2021 in accordance with the terms of the Offer to Purchase dated February 4, 2021 (the “Offer to Purchase”):

2023 Pool

Offers to purchase for cash up to $950,000,000 aggregate purchase price for the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP/ISIN Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline	Principal Amount Accepted	Offer Yield(1)	Approximate Proration Factor	Total Consideration(2)
1	7.150% Notes due 2023	110122AA6	Bristol Myers Squibb	$301,532,000	$62,818,000	$62,818,000	0.259%	100%	$1,158.68
2	4.000% Notes due 2023	110122DA3/ 110122BL1/ U11009AL8	Bristol Myers Squibb	$636,086,000	$256,371,000	$256,371,000	0.353%	100%	$1,089.89
2	4.000% Notes due 2023	151020AJ3	Celgene	$63,914,000	$14,081,000	$14,081,000	0.353%	100%	$1,089.89

2024 Pool

Offers to purchase for cash up to $1,500,000,000 aggregate purchase price for the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP/ISIN Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline	Principal Amount Accepted	Offer Yield(1)	Approximate Proration Factor	Total Consideration(2)
1	3.625% Notes due 2024*	110122DB1/ 110122BM9/ U11009AM6	Bristol Myers Squibb	$882,510,000	$582,075,000	$582,075,000	0.351%	100%	$1,096.90
1	3.625% Notes due 2024*	151020AP9	Celgene	$117,490,000	$22,619,000	$22,619,000	0.351%	100%	$1,096.90
2	2.900% Notes due 2024	110122CM8/ 110122BZ0/ U11009AZ7	Bristol Myers Squibb	$3,250,000,000	$2,132,607,000	$772,109,000	0.436%	36.23%	$1,083.67

2025 Pool

Offers to purchase for cash up to $650,000,000 aggregate purchase price for the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP/ISIN Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline	Principal Amount Accepted	Offer Yield(1)	Approximate Proration Factor	Total Consideration(2)
1	3.875% Notes due 2025*	110122DC9/ 110122BN7/ U11009AN4	Bristol Myers Squibb	$2,379,532,000	$1,054,294,000	$557,311,000	0.724%	52.90%	$1,130.97
1	3.875% Notes due 2025*	151020AS3	Celgene	$120,468,000	$33,453,000	$17,418,000	0.724%	52.90%	$1,130.97

High Coupon Pool

Offers to purchase for cash up to $900,000,000 aggregate purchase price for the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP/ISIN Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline	Principal Amount Accepted	Offer Yield(1)	Approximate Proration Factor	Total Consideration(2)
1	6.125% Notes due 2038	110122AQ1	Bristol Myers Squibb	$226,259,000	$7,004,000	$7,004,000	3.031%	100%	$1,412.08
2	5.875% Notes due 2036	110122AP3	Bristol Myers Squibb	$286,673,000	$7,453,000	$7,453,000	2.931%	100%	$1,368.80
3	6.875% Notes due 2097	110122AC2	Bristol Myers Squibb	$86,896,000	$1,169,000	$1,169,000	3.781%	100%	$1,771.55
Bristol-Myers Squibb Co NYSE:BMY BMY Rankings #105 Ranked by Market Cap #614 Ranked by Dividends BMY Latest News May 6, 2025 Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Apr 24, 2025 Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Apr 22, 2025 Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia Apr 17, 2025 U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications Apr 15, 2025 Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis BMY Stock Data Market Cap 102.91B Float 2.03B Insiders Ownership 0.1% Institutions Ownership 80.86% Short Percent 1.51% Industry Drug Manufacturers - General Sector Pharmaceutical Preparations Website Link Country United States City PRINCETON Explore About Rhea-AI Sitemap Legal Terms of Use Cookie Notice Privacy Policy Links RSS feed Discord Server Facebook Reddit © 2020-2025 StockTitan.net Login Please enter your login and password Email address Password Forgot password? LOGIN Close Don't have an account? Sign Up! Forgot Password Please enter your email address Email address RECOVER Close Sign Up To create a free account, please fill out the form below. Username Email address Password I accept the user agreement Sign me up for the newsletter CREATE ACCOUNT Close Already have an account? Login